Widaplik is a drug owned by George Medicines Pty Ltd. It is protected by 2 US drug patents filed in 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 23, 2038. Details of Widaplik's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10799487 | Compositions for the treatment of hypertension |
Jan, 2038
(12 years from now) | Active |
| US10322117 | Compositions for the treatment of hypertension |
Jan, 2038
(12 years from now) | Active |
US patents provide insights into the exclusivity only within the United States, but Widaplik is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Widaplik's family patents as well as insights into ongoing legal events on those patents.
Widaplik's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Widaplik's generic launch date based on the expiry of its last outstanding patent is estimated to be Jan 23, 2038 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Widaplik Generics:
There are no approved generic versions for Widaplik as of now.
Alternative Brands for Widaplik
There are several other brand drugs in the same treatment category as Widaplik. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Azurity |
| |||
About Widaplik
Widaplik is a drug owned by George Medicines Pty Ltd. Widaplik uses Amlodipine Besylate; Indapamide; Telmisartan as an active ingredient. Widaplik was launched by George Medicines in 2025.
Approval Date:
Widaplik was approved by FDA for market use on 05 June, 2025.
Active Ingredient:
Widaplik uses Amlodipine Besylate; Indapamide; Telmisartan as the active ingredient. Check out other Drugs and Companies using Amlodipine Besylate; Indapamide; Telmisartan ingredient
Dosage:
Widaplik is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 1.25MG BASE;0.625MG;10MG | TABLET | Discontinued | ORAL |
| EQ 5MG BASE;2.5MG;40MG | TABLET | Discontinued | ORAL |
| EQ 2.5MG BASE;1.25MG;20MG | TABLET | Discontinued | ORAL |